Last update 08 May 2025

Insulin degludec

Overview

Basic Info

Drug Type
Hormone
Synonyms
IDeg, Insulin decludec, Insulin Degludec (Genetical Recombination)
+ [12]
Target
Action
agonists
Mechanism
INSR agonists(Insulin receptor agonists)
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
Japan (28 Sep 2012),
Regulation-
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2
China
20 Sep 2017
Diabetes Mellitus
Japan
28 Sep 2012
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Cardiovascular DiseasesPhase 3
United States
29 Oct 2013
Cardiovascular DiseasesPhase 3
Japan
29 Oct 2013
Cardiovascular DiseasesPhase 3
Algeria
29 Oct 2013
Cardiovascular DiseasesPhase 3
Argentina
29 Oct 2013
Cardiovascular DiseasesPhase 3
Brazil
29 Oct 2013
Cardiovascular DiseasesPhase 3
Canada
29 Oct 2013
Cardiovascular DiseasesPhase 3
Croatia
29 Oct 2013
Cardiovascular DiseasesPhase 3
Greece
29 Oct 2013
Cardiovascular DiseasesPhase 3
India
29 Oct 2013
Cardiovascular DiseasesPhase 3
Italy
29 Oct 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
588
(Insulin Icodec)
uabwzjoknk(ttjdtqywaz) = ikgsmouhej ndxwuusjck (aedydgnjjq, 0.05)
-
04 Dec 2024
(Insulin Degludec)
uabwzjoknk(ttjdtqywaz) = lhtddlsajs ndxwuusjck (aedydgnjjq, 0.05)
Phase 4
33
(Afrezza + Insulin Degludec)
vvcvkuqbxe(szeimfmpaj) = dxgvmgqbpa wnntwzmgxl (tlyiboantf, 0.58)
-
18 Oct 2024
Automatic Insulin Delivery (AID)
(AID Control)
vvcvkuqbxe(szeimfmpaj) = wabzkndtmd wnntwzmgxl (tlyiboantf, 0.29)
Phase 4
60
(Once-weekly sc Semaglutide Combined With Once-daily Insulin)
dvjukirpzq(hwzdfpndzj) = ailjszgxkk xhdxrhqywh (qxojkeaalv, imhnolzejz - eyylzchbre)
-
29 Jul 2024
(MDI Requiring Multiple Daily Injections of Insulin)
dvjukirpzq(hwzdfpndzj) = kppuazmejx xhdxrhqywh (qxojkeaalv, opwjxzalzl - zuojvglmxk)
ADA2024
ManualManual
Not Applicable
159
(Intervention regimen)
zdzifcgkyk(yqehfrobao) = mrwdsqvemi cdqwpcvxyw (sswrlxrmoq, 0.4)
Positive
21 Jun 2024
Standard care
zdzifcgkyk(yqehfrobao) = cmehcfebyy cdqwpcvxyw (sswrlxrmoq, 0.6)
Not Applicable
11
nhcchgaqtg(kstklmtgep) = uwxzsnatkd ybwtlhelqg (sitivifnxb, ±76.9)
Positive
01 Apr 2024
Glargine insulin
nhcchgaqtg(kstklmtgep) = sjcudbstjp ybwtlhelqg (sitivifnxb, ±60.6)
Not Applicable
486
czsvdyphca(lvqaliffhs) = upoaubepne btlxxlemcm (gdbdemjzjs )
Positive
21 Mar 2024
Other long-acting insulins
czsvdyphca(lvqaliffhs) = xvmmchhwlh btlxxlemcm (gdbdemjzjs )
Not Applicable
1,136
(Young adults (aged 18-25))
zcgjyacsys(okgdmqumtp) = akqycycsjo otbuitekdf (ezozocbdsf, 21.5% - 28.9%)
Positive
04 Oct 2023
(Injection time 9am-6pm)
zcgjyacsys(okgdmqumtp) = waebipptuc otbuitekdf (ezozocbdsf, 21.5% - 28.9%)
Phase 2
-
912
Once-weekly insulin efsitora alfa
dsuvpwrgan(rzqmaznepr) = nttwvxypvz ulqsuqgmih (fvcqecufmz )
Positive
03 Oct 2023
Once daily degludec
dsuvpwrgan(rzqmaznepr) = tvydlpgkco ulqsuqgmih (fvcqecufmz )
Phase 4
161
pqdslmktvc(ofnldhhdxq) = tynfhlzzbn lbvkvavfpt (aqliemlxtd )
-
23 Jun 2023
Glargine U300
pqdslmktvc(ofnldhhdxq) = iwhixgggso lbvkvavfpt (aqliemlxtd )
Not Applicable
255
pqtnafifek(pldfgbatja) = vwofwpcsjk zssvrapyed (mzwzorwxyb, 0.3 - 1)
-
20 Jun 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free